<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212235</url>
  </required_header>
  <id_info>
    <org_study_id>Hypofractionated GBM</org_study_id>
    <nct_id>NCT03212235</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiation Therapy for Glioblastoma</brief_title>
  <official_title>Hypofractionated Radiation Therapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Notwithstanding major improvements in treatment modalities, the prognosis of patients with
      glioblastoma is poor. Hypofractionated radiation therapy as an alternative of the standard
      6-week regimen could be an attractive approach as an effort to prevent tumor cell
      repopulation and reduction the total treatment period promoting patient comfort and
      convenience.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>From date of the start of treatment to date of death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>The time between the start of treatment and tumor progression or death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Hypofractionated radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.
After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiation therapy</intervention_name>
    <description>Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)</description>
    <arm_group_label>Hypofractionated radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 to 70 years of age with newly diagnosed and histologically confirmed
             glioblastoma.

          -  WHO performance status of 2 or less and adequate hematologic, renal, and hepatic
             function.

        Exclusion Criteria:

          -  Prior diagnosis of cancer, unless disease free for &gt; 3 years

          -  Previous history of radiotherapy in the head and neck region (except initial larynx
             tumor - T1, T2 / N0M0).

          -  Specific severe, active co-morbidities

          -  Tumor located in the brainstem

          -  Presence of leptomeningeal carcinomatosis

          -  Multicentric tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gustavo N Marta, PhD</last_name>
    <phone>551138934538</phone>
    <email>gustavo.marta@hc.fm.usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de São Paulo (ICESP) - FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo N Marta, PhD</last_name>
      <phone>55+11+38934538</phone>
      <email>gustavo.marta@hc.fm.usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto do Cancer do Estado de São Paulo</investigator_affiliation>
    <investigator_full_name>Gustavo Nader Marta</investigator_full_name>
    <investigator_title>Radiation Oncologist and Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

